Everything's Fine

What''s at stake when you fall in love? When Jess first meets Josh at their Ivy League college she dislikes him immediately. Josh stands for everything that Jess opposes: a handsome white guy in chinos, ready to take over the world. Meanwhile Jess is almost always the only black woman in their class. She''s sick of the casual racism, the class debates about affirmative action, and she''s especially sick of insensitive, know-it-all, Josh, who isn''t shy about broadcasting his infuriating opinions. But when, after graduating, Jess and Josh end up working together in the same bank, talking about the things they both love, equally despising their awful boss, it seems their connection might be deeper than Jess ever could have imagined. As their tempestuous friendship turns into an electrifying romance that shocks them both, Jess begins to question who she is and what she''s really willing to compromise for love. ''A stunning debut'' - Meg Mason, author of Sorrow and Bliss ''Original, confident, hilarious'' - Sathnam Sanghera, author of Empireland

About the author

Cecilia Rabess previously worked as a data scientist at Google and as an associate at Goldman Sachs. Her nonfiction has been featured in McSweeneys, FiveThirtyEight, Fast Company, and FlowingData, among other places. Everything's Fine is her debut novel.

Product details

• Authors: Cecelia Rabess, Cecilia Rabess
• Publisher: Picador Uk
• Languages: English
• Age Recommendation: from age 18
• Product format: Paperback / Softback
• Released: 01.06.2023
• EAN: 9781529083187
• ISBN: 978-1-5290-8318-7
• No. of pages: 326
• Dimensions: 153 mm x 234 mm x 26 mm
• Subjects: Fiction > Narrative literature; New York, Manhattan, Adult & contemporary romance, FICTION / Literary, FICTION / City Life, FICTION / Political, FICTION / Romance / Multicultural & Interracial, FICTION / Romance / Workplace, Coping with death & bereavement, Narrative theme: Death, grief, loss, Narrative theme: Politics, Narrative theme: Identity / belonging, Narrative theme: Love and relationships, c 2010 to c 2020, Early 21st century c 2000 to c 2050, Pharmaceutical industries